INSMED Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
VA
Business Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
Mailing Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
Phone
908-977-9900
Fiscal Year End
1231
EIN
541972729
Financial Overview
FY2025
$2.26B
Total Assets
$555.03M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 1, 2026 | View on SEC |
| 4 Insider stock transaction report | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 4 Insider stock transaction report | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 25, 2026 | View on SEC |
Annual Reports
10-K
February 19, 2026
- ARIKAYCE sales drove 10% revenue growth to $850 million, with 2025 revenue projected up to $950 million.
- Strategic pipeline expansion through acquisitions like Motus Biosciences, with a lead candidate entering Phase 2 trials ahead of schedule.
Material Events
8-K
Strategy Change
December 17, 2025
High Impact
- INSMED Inc. discontinued the development of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) due to insufficient results in its Phase 2b study.
- The company acquired a new potential drug, INS1148, which it plans to develop for interstitial lung disease and moderate-to-severe asthma.
Insider Trading
STRONG SELL
7 insiders
89 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.